The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
复制标题
DOI：
10.7150/jca.13711
复制
发表时间：
2016
影响因子：
3.9
通讯作者：
Park YS
中科院分区：
文献类型：
--
作者：
Kim ST;Ha SY;Lee S;Ahn S;Lee J;Park SH;Park JO;Lim HY;Kang WK;Kim KM;Park YS
程序性死亡配体1(PD-L1)表达于多种肿瘤细胞上，与表达于T细胞表面的PD1相互作用，抑制T细胞，阻断抗肿瘤免疫反应。PD-L1在胃肠胰脏神经内分泌肿瘤(GEP-Nets)中的表达尚未见报道。我们研究了PD-L1在32例转移性GEP-Net患者中表达的影响。用针对福尔马林固定石蜡包埋(FFPE)组织标本染色的抗PD-L1免疫组织化学(IHC)抗体评价PD-L1的表达。分析PD-L1与生存期和全身治疗反应等临床病理资料的相关性。24个前肠来源的GEP网络，包括胃(n=1)、十二指肠(n=2)、胆道(n=7)和胰腺(n=14)，以及8个后肠来源的远端结肠和直肠GEP-Net。在本研究分析的32例转移性GEP-Net患者中，7例(21.9%)在肿瘤组织中有PD-L1的表达。PD-L1的表达与WHO高级别分级(3级)显著相关(p=0.008)，但与性别、原发部位和转移部位数目无关(p>；0.05)。PD-L1的表达状态与一线全身治疗的无进展生存期(PFS)有统计学相关性(p=0.047)。此外，PD-L1的表达状态可以显著预测总的生存期(p=0.037)。PD-L1的表达与转移性GEP-Net的WHO分级(3级)有关。PD-L1的表达对转移性GEP-Net患者的生存有预测和预后价值。
Programmed death-ligand 1 (PD-L1), which is expressed on many cancer cells, interacts with PD1 expressed on the surface of T cells, inhibiting the T cells and blocking the antitumor immune response. Expression of PD-L1 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has not been studied. We investigated the impact of PD-L1 expression in 32 patients with metastatic GEP-NET. The expression of PD-L1 was evaluated using an anti-PD-L1 immunohistochemistry (IHC) antibody optimized for staining of formalin-fixed paraffin-embedded (FFPE) tissue samples. The correlation between PD-L1 and clinicopathological data including survival and response to systemic treatments was analyzed. Primary sites were 24 foregut-derived GEP-NETs, including stomach (n=1), duodenum (n=2), biliary tract (n=7), and pancreas (n=14), and 8 hindgut-derived GEP-NETs of the distal colon and rectum. Among the 32 patients with metastatic GEP-NET analyzed in this study, 7 (21.9%) had expression of PD-L1 in tumor tissues. Expression of PD-L1 was significantly associated with high-grade WHO classification (grade 3) (p=0.008) but not with gender, primary site, and number of metastatic sites (p>0.05). The status of PD-L1 expression was statistically associated with progression-free survival (PFS) for first-line systemic treatment (p=0.047). Moreover, the status of PD-L1 expression could significantly predict overall survival (p=0.037). The expression of PD-L1 was associated with higher WHO tumor grade (grade 3) in metastatic GEP-NETs. PD-L1 expression had both predictive and prognostic value for survival of patients with metastatic GEP-NETs.